Oncosil Medical (OSL) Q1 2025 TU earnings summary

Executive summary

• Q1 FY25 revenue reached $0.166 million, with 12-month sales rising to $0.7 million, up from $0.2 million year-over-year.

• First commercial patient in Türkiye successfully underwent surgical resection after OncoSil™ treatment.

• 30th patient treated in Spain, with 12 active sites and 4 more ready to commence treatments.

• 50% recruitment achieved in both TRIPP-FFX and PANCOSIL clinical trials, marking key milestones.

• G-BA approval in Germany paves way for a randomized controlled trial under a Coverage with Evidence Development program.

Financial highlights

• Q1 FY25 sales revenue was $0.166 million; 12-month revenue to 30 September 2024 totaled $0.7 million, up from $0.2 million year-over-year.

• Net cash used in operating activities for Q1 was $(3.2) million.

• Cash and cash equivalents at quarter end were $4.0 million, down from $4.5 million at the start of the quarter.

• $2.7 million raised via placement to an Australian institutional investor during the quarter.

Outlook and guidance

• Management expects ongoing commercialization efforts in multiple markets to drive sales growth over the next 12 months.

• Additional $7 million placement and $1 million share purchase plan announced post-quarter to support operations.

• Focus remains on expanding access to OncoSil™ and achieving further clinical and regulatory milestones.